Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
Delayed Quote. Delayed Euronext Paris - 12/02 11:35:14 am
4.4 EUR   -3.93%
01:00aINNATE PHARMA : 2021 financial calendar
GL
01:00aInnate Pharma 2021 Financial Calendar
GL
11/18INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Innate Pharma : Gets $50 Million Milestone Payment From AstraZeneca

10/23/2020 | 07:46am EST

By Chris Wack

Innate Pharma SA said Friday that AstraZeneca has dosed the first patient in its Phase 3 clinical trial evaluating monalizumab in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Dosing of the first patient in the trial has triggered a $50 million milestone payment from AstraZeneca to Innate.

Innate said the milestone payment fortifies its cash position through the end of 2022.

The company said the combination of monalizumab and cetuximab demonstrated a manageable safety profile and a response rate of 27.5%.

Innate Pharma shares were up 12%, to $4.41, in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

10-23-20 0745ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.26% 7937 Delayed Quote.4.34%
INNATE PHARMA -3.93% 4.4 Real-time Quote.-26.17%
All news about INNATE PHARMA
01:00aINNATE PHARMA : 2021 financial calendar
GL
01:00aInnate Pharma 2021 Financial Calendar
GL
11/18INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
11/17INNATE PHARMA : Revenue for Q3
PU
11/17INNATE PHARMA : reports third quarter 2020 financial results and business update
PU
11/17INNATE PHARMA : Reports Third Quarter 2020 Financial Results and Business Update
AQ
11/17INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
11/17Innate Pharma Reports Third Quarter 2020 Financial Results and Business Updat..
GL
11/17INNATE PHARMA : reports third quarter 2020 financial results and business update
GL
11/17INNATE PHARMA : 3rd quarter results
CO
More news
Financials
Sales 2020 88,8 M 107 M 107 M
Net income 2020 -29,9 M -36,2 M -36,2 M
Net cash 2020 109 M 132 M 132 M
P/E ratio 2020 -5,41x
Yield 2020 -
Capitalization 347 M 420 M 420 M
EV / Sales 2020 2,69x
EV / Sales 2021 5,00x
Nbr of Employees 247
Free-Float 75,3%
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 7,98 €
Last Close Price 4,58 €
Spread / Highest target 140%
Spread / Average Target 74,1%
Spread / Lowest Target -12,7%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA-23.15%436
MODERNA, INC.620.91%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.90.06%41 539
IQVIA HOLDINGS INC.10.82%32 829
SEAGEN INC.55.27%31 988